Add thelocalreport.in As A Trusted Source
NHS The US President may have to pay more for medicines under a plan to stop the threatened tariff Donald TrumpThis has been told.
Politico reported that information was given about proposals, including increasing the range used by the NHS expenditure monitoring of England to 25%. Washington Officers.
The government has confirmed that it is “advanced discussion” with the US to “ensure the best results for the UK”.
National health and care institute (Nice) evaluates drugs based on several factors including clinical effectiveness, cost effectiveness and overall cost of NHS.
This is done using evaluation called QALYS, which refers to both the length of life and its effect on the quality of life as a number.
In general, Nice considers drugs between £ 20,000 and £ 30,000 obtained per additional QALY to represent good value for money for NHS.
Increasing the limit will make access to more expensive drugs for NHS patients, but this will also mean that healthcare will pay more for medicines overall.
It comes after the Minister of Science, Lord Patrical valges It was accepted that an increase in the price paid by NHS for drugs would be “necessary” to prevent pharmaceutical investment from leaving the UK.
Major companies have stopped or stopped investment schemes in the UK Pharmaceutical Industry this year, and industry owners recently told MPs that the “difficult” environment and pressure on pricing have created a less attractive investment environment than other countries like America.
It is understood that President Trump wants more equality on drug pricing, as drug prices in the US are more in the world and have threatened to impose a tariff of up to 100% on pharmaceutical imports.
A government spokesperson said: “The pharmaceutical sector and the new medicines produced by it are important for our NHS, our economy and the plan of change.
“Through our Life Sciences Area Scheme, we are committed to working with the industry to accelerate the increase in spending on new drugs compared to the previous decade.
“We have achieved a historic economic partnership with the US that includes working together on pharmaceutical exports from the UK and improving conditions for pharmaceutical companies here.
“Now we are holding advanced discussions with the US administration to ensure the best results for the UK, which reflects our strong relationships and close partnership opportunities with our pharmaceutical industry.”